According to Immix Biopharma's latest financial reports the company has a price-to-book ratio of 0.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | 3.51 | -58.62% |
2023-12-31 | 8.48 | 250.1% |
2022-12-31 | 2.42 | 61.68% |
2021-12-31 | 1.50 | |
2020-12-31 | N/A |